Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 13/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 13/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 11/20 | 0.74 |
| ▸ | HSD17B10 | Q99714 | 11/20 | 0.74 |
| ▸ | MAPT | P10636 | 11/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.74 |
| ▸ | TP53 | P04637 | 8/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.74 |
| ▸ | HPGD | P15428 | 8/20 | 0.74 |
| ▸ | CASP1 | P29466 | 6/20 | 0.74 |
| ▸ | CASP7 | P55210 | 6/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 6/20 | 0.74 |
| ▸ | ALOX15 | P16050 | 6/20 | 0.74 |
| ▸ | LMNA | P02545 | 4/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.74 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.69 |
| ▸ | RECQL | P46063 | 4/20 | 0.69 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.69 |
| ▸ | CDK5R1 | Q15078 | 3/20 | 0.69 |
| ▸ | XDH | P47989 | 3/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL119655 | 0.92 | MEN1 (0.73) | MEN1KMT2ACYP3A4HSD17B10MAPT | |
| SCHEMBL13056278 | 0.88 | MEN1 (0.61) | MEN1KMT2ACYP3A4HSD17B10MAPT | |
| SCHEMBL13076836 | 0.87 | MEN1 (0.63) | MEN1KMT2ACYP3A4HSD17B10MAPT | |
| Geraldol SCHEMBL29394734 | 0.85 | MEN1 (1.00) | MEN1KMT2ACYP3A4HSD17B10MAPT | |
| Geraldol SCHEMBL620712 | 0.85 | MEN1 (1.00) | MEN1KMT2ACYP3A4HSD17B10MAPT | |
| Geraldol SCHEMBL31122383 | 0.85 | MEN1 (1.00) | MEN1KMT2ACYP3A4HSD17B10MAPT | |
| SCHEMBL3718642 | 0.84 | MEN1 (0.72) | MEN1KMT2ACYP3A4HSD17B10MAPT | |
| SCHEMBL3715897 | 0.84 | MEN1 (0.69) | MEN1KMT2ACYP3A4HSD17B10MAPT | |
| SCHEMBL3718644 | 0.83 | MEN1 (0.71) | MEN1KMT2ACYP3A4HSD17B10MAPT | |
| Fisetin SCHEMBL4466733 | 0.83 | MEN1 (0.90) | MEN1KMT2ACYP3A4HSD17B10MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2424541-A2 | PHOSPHORYLATED AND PHOSPHONATED PYRONE ANALOGS FOR THERAPEUTIC TREATMENT | Limerick BioPharma, Inc. (US) | 2012-03-07 | — | — | EP | disclosed |
| EP-2355814-A2 | PYRONES FOR THE TREATMENT OF METABOLIC DISORDERS | Limerick BioPharma, Inc. (US) | 2011-08-17 | — | — | EP | disclosed |
| US-20100297020-A1 | PHOSPHORYLATED AND PHOSPHONATED PYRONE ANALOGS FOR THERAPEUTIC TREATMENT | LIMERICK BIOPHARMA, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| WO-2010129138-A2 | PHOSPHORYLATED AND PHOSPHONATED PYRONE ANALOGS FOR THERAPEUTIC TREATMENT | LIMERICK BIOPHARMA (US) | 2010-11-11 | — | — | WO | disclosed |
| US-20100189653-A1 | Pyrone analogs for therapeutic treatment | LIMERICK BIOPHARMA, INC. | 2010-07-29 | — | — | US | disclosed |
| WO-2010042886-A2 | PYRONE ANALOGS FOR THERAPEUTIC TREATMENT | LIMERICK BIOPHARMA, INC. (US) | 2010-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100297020-A1 | PHOSPHORYLATED AND PHOSPHONATED PYRONE ANALOGS FOR THERAPEUTIC TREATMENT | PC, PCK1, PYGL | MEN1 2302/4885KMT2A 4512/4885CYP3A4 2300/4885 |
| US-20100189653-A1 | Pyrone analogs for therapeutic treatment | PC, GLS2, CYP27A1 | MEN1 1731/4885KMT2A 4385/4885CYP3A4 718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.